Vessi Medical
Vessi Medical uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue in order to treat superficial bladder cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | $16.5m | Series A | |
| Total Funding | 000k | ||
Related Content
Vessi Medical is a medical device company focused on the urological sector, specifically in the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC). The company has developed a proprietary system that utilizes surface cryotherapy, a process involving extreme cold, to ablate cancerous tissue within the bladder.
The core of its offering is a minimally invasive cryospray system designed for use in hollow and humid organs. This technology provides a therapeutic alternative to traditional procedures for NMIBC. The treatment is delivered transurethrally, aiming to reduce the invasiveness of the procedure for the patient. The business model is centered on the development and commercialization of this medical device, targeting healthcare providers in the urology market. The company generates revenue through the sale of its cryotherapy systems and potentially recurring sales of disposables or related components.
Based in Israel, the company has secured funding to advance its technology, including a significant Series A round, indicating investor confidence in its approach to bladder cancer treatment.
Keywords: cryotherapy, medical device, urology, bladder cancer, NMIBC, minimally invasive, cryospray, oncology, surgical device, transurethral